Shots:

• The US FDA has granted FTD for VX-880 to treat T1D. The designation is designed to facilitate the development and expedite the review of treatments for serious condition and fill an unmet medical need
• Additionally- the company has initiated P-I/II trial for VX-880 in ~17 patients who have T1D with severe hypoglycemia and impaired hypoglycemic awareness
• VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated- insulin-producing pancreatic islet cells for the treatment of T1D

 ­ Ref: Businesswire | Image: Vertex